GlassScriptPhysician profile
Shiva Barforoshi
NPI 1487277265
$2,609.37
in general payments reported to CMS, 2019-2025
20 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.72 · 2023: $32.96 · 2024: $668 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479 · Gift: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,479.27 |
| Gift | $114.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $475.09 | 2025 | Rapiblyk |
| Abiomed | $328.68 | 2024-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $270.66 | 2024-2025 | Evkeeza |
| Shockwave Medical, INC | $267.69 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $234.66 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.61 | 2025 | Lifevest |
| Edwards Lifesciences Corporation | $173.68 | 2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $116.22 | 2025 | |
| Merck Sharp & Dohme LLC | $84.88 | 2024-2025 | Winrevair |
| Scpharmaceuticals INC. | $66.39 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $58.78 | 2025 | Wainua |
| Janssen Pharmaceuticals, INC | $57.30 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $53.59 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $49.29 | 2024 | Arcalyst |
| Jazz Pharmaceuticals INC. | $32.96 | 2023 | Zepzelca |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $31.36 | 2025 | Pemgarda |
| Terumo Medical Corporation | $29.13 | 2025 | Tr Band, Angio-Seal |
| Cardiva Medical, INC. | $15.21 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Chiesi USA, INC. | $14.78 | 2025 | Kengreal |
| Abbott Laboratories | $14.41 | 2025 | Merlin@Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiva Barforoshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.